Results 21 to 30 of about 18,139 (185)

Low-dose naltrexone-induced remission in Hailey–Hailey disease maintained in remission with topical combination of ketamine and diphenhydramine

Indian Dermatology Online Journal, 2019
Recent anecdotal evidence suggests that oral low-dose naltrexone (LDN) is effective for Hailey–Hailey disease (HHD) but suffers the limitation of immediate relapse following cessation of the medication.
Sidharth Sonthalia, Mahima Agrawal, Ankur Talwar, Mohamad Goldust   +3 more
doaj   +1 more source

Naltrexone Inhibits IL-6 and TNFα Production in Human Immune Cell Subsets following Stimulation with Ligands for Intracellular Toll-Like Receptors

Frontiers in Immunology, 2017
The opioid antagonist naltrexone hydrochloride has been suggested to be a potential therapy at low dosage for multiple inflammatory conditions and cancers.
Rachel Cant, Angus G. Dalgleish, Rachel L. Allen   +2 more
doaj   +1 more source

A Case Report of a Dual Diagnosis Patient: Naltrexone for the Treatment of Severe Nitrous Oxide Use Disorder with Associated Neurological and Psychiatric Sequelae

Journal of Scientific Innovation in Medicine, 2023
Background: Nitrous oxide (N2O) is a non-regulated substance with increasing prevalence as a drug of abuse. N2O abuse is associated with both neurological and psychiatric sequelae, including psychotic symptoms.
Paige Juliet Staudenmaier, Veronica Kane, Amulya Iyer, Paul Campion   +3 more
doaj   +1 more source

Naltrexone Treatment for Methamphetamine Dependence – Service Evaluation Audit

BJPsych Open
Aims There is an emerging evidence base to support the benefit of naltrexone prescription in methamphetamine dependence. This audit assesses prescribing practice and benefit of naltrexone in a specialist NHS drug service based in West London.
Emma Stimson, Owen Bowden-Jones
doaj   +1 more source

Naltrexone therapeutic drug monitoring: A case series

Psychiatry and Clinical Psychopharmacology, 2021
Objective: Naltrexone is an opioid receptor antagonist.It is used in maintanence treatment of opiate dependence,alcohol dependence, prevention of relapse of alcohol dependence, treatment of cocaine dependence, nicotine dependence, eating disorders ...
Birim Sungu Danışmant, Nesrin Dilbaz, Esra Sağlam, Kaşif Nevzat Tarhan   +3 more
doaj  

Intranasal Low-Dose Naltrexone Against Opioid Side Effects: A Preclinical Study

Frontiers in Pharmacology, 2020
Opioids are broad spectrum analgesics that are an integral part of the therapeutic armamentarium to combat pain in the clinical practice. Unfortunately, together with analgesia, a number of adverse effects can occur such as nausea, vomiting, constipation,
Laura Micheli, Lorenzo Di Cesare Mannelli, Elena Lucarini, Carmen Parisio, Alessandra Toti, Bruno Fiorentino, Maria Adele Rigamonti, Laura Calosi, Carla Ghelardini   +8 more
doaj   +1 more source

Naltrexone Reverses Ethanol Preference and Protein Kinase C Activation in Drosophila melanogaster

Frontiers in Physiology, 2018
Alcohol use disorder (AUD) is a major health, social and economic problem for which there are few effective treatments. The opiate antagonist naltrexone is currently prescribed clinically with mixed success.
Rajeswari Koyyada, Nilesh Latchooman, Julius Jonaitis, Samir S. Ayoub, Olivia Corcoran, Stefano O. Casalotti   +5 more
doaj   +1 more source

Quantitative Determination of Naltrexone Hydrochloride in a Nasal Spray by High-performance Liquid Chromatography

Разработка и регистрация лекарственных средств, 2020
Introduction. Naltrexone, an antagonist of µ-opioid receptors, is promising for the treatment of various autoimmune and oncological diseases when used in doses of 1.5–5 mg/day. To date, there are no medications that provide such dosages of naltrexone.Aim.
Yu. M. Domnina, V. V. Suslov, S. A. Kedik, E. V. Vorfolomeeva, A. V. Meleshko   +4 more
doaj   +1 more source

Trends in Use of Obesity Medications and Metabolic and Bariatric Surgery Among All of Us Participants From 2003 to 2023

Obesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate the trends in antiobesity medication (AOM) and metabolic and bariatric surgery (MBS) use relative to the 2013 American Medical Association (AMA) declaration of obesity as a chronic disease and semaglutide approval in 2021 in the United States.
Olajide A. Adekunle, Phuc Le, Christopher Boyer, Hamlet Gasoyan, Dev Yash Gupta, Ha T. Tran, Yihua Yue, Michael B. Rothberg   +7 more
wiley   +1 more source

Twenty‐Four Month Outcomes From a Real‐World Telehealth Obesity Treatment Clinic Using Obesity Medications

Obesity, EarlyView.
ABSTRACT Objective Antiobesity medications (AOMs) are indicated for long‐term use; however, evidence of their real‐world long‐term efficacy is limited. This study describes clinical outcomes from 18‐ and 24‐month use of AOMs in a telemedicine weight management clinic.
Kathleen R. Ruddiman, Young‐Rock Hong, Jamy Ard, Rebecca Jones, Adam Medcalf, Gary D. Foster, Jamil Alkhaddo, Michelle Cardel   +7 more
wiley   +1 more source